MicroRNA profiling as tool for in vitro developmental neurotoxicity testing: The case of sodium valproate

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Smirnova, Lena ^a,b   Block, Katharina ^a,c   Sittka, Alexandra ^a,d   Oelgeschläger, Michael ^a   Seiler, Andrea E M ^a   Luch, Andreas ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF POTSDAM   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENITE SODIUM; HISTONE DEACETYLASE; MESSENGER RNA; MICRORNA; MICRORNA 10A; MICRORNA 124A; MICRORNA 128; MICRORNA 133A; MICRORNA 137; MICRORNA 206; MYOGENIC FACTOR; TRANSCRIPTOME; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; GABAERGIC RECEPTOR AFFECTING AGENT; HISTONE DEACETYLASE INHIBITOR;

ACTC1 GENE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASPORIN GENE; CALPONIN GENE; CELL VIABILITY; CONTROLLED STUDY; DECORIN GENE; DOWN REGULATION; EMBRYO; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; IMMUNOCHEMISTRY; IN VITRO STUDY; LONG TERM EXPOSURE; MOUSE; MYOSIN LIGHT CHAIN GENE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OTX1 GENE; OTX2 GENE; REAL TIME POLYMERASE CHAIN REACTION; TOXICITY TESTING; UPREGULATION; VALIDATION PROCESS; ZIC3 GENE; ZIC4 GENE; ZIC5 GENE; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CLUSTER ANALYSIS; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MUSCLE DEVELOPMENT; NERVE CELL; PROCEDURES; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TIME; TOXICITY AND INTOXICATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CLUSTER ANALYSIS; DRUG DISCOVERY; EMBRYONIC STEM CELLS; GABA AGENTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HISTONE DEACETYLASE INHIBITORS; IN VITRO TECHNIQUES; MICE; MICRORNAS; MUSCLE DEVELOPMENT; NEURONS; NEUROTOXICITY SYNDROMES; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TIME FACTORS; VALPROIC ACID;

EID: 84902531897     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098892     Document Type: Article

References (95)

1. Grandjean P, Landrigan PJ (2006) Developmental neurotoxicity of industrial chemicals. Lancet 368: 2167-2178. doi:10.1016/S0140-6736(06)69665-7. (Pubitemid 44894541)
2. Landrigan PJ (2010) What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 22: 219-225. doi:10.1097/MOP.0-b013e328336eb9a.
3. Rice DD, Barone SS (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108 Suppl 3: 511-533.
4. Kuehn BM (2010) Increased Risk of ADHD Associated With Early Exposure to Pesticides, PCBs. JAMA 304: 27-28. doi:10.1001/jama.2010.860.
5. Sagiv SKS, Thurston SWS, Bellinger DCD, Tolbert PEP, Altshul LML, et al. (2010) Prenatal organochlorine exposure and behaviors associated with attention deficit hyperactivity disorder in school-aged children. Am J Epidemiol 171: 593-601. doi:10.1093/aje/kwp427.
6. Boyle CA, Decouflé P, Yeargin-Allsopp M (1994) Prevalence and health impact of developmental disabilities in US children. Pediatrics 93: 399-403. (Pubitemid 24067011)
7. Schettler TT (2001) Toxic threats to neurologic development of children. Environ Health Perspect 109 Suppl 6: 813-816.
8. Buschmann J (2013) The OECD guidelines for the testing of chemicals and pesticides. Methods MolBiol 947: 37-56. doi:10.1007/978-1-62703-131-8-4.
9. Boyes WK, Dourson ML, Patterson J, Tilson HA, Sette WF, et al. (1997) EPA's neurotoxicity risk assessment guidelines. Vol. 40. pp. 175-184.
10. Lein P, Silbergeld E, Locke P, Goldberg AM (2005) In vitro and other alternative approaches to developmental neurotoxicity testing (DNT). Environ Toxicol Pharmacol 19: 735-744. doi:10.1016/j.etap.2004.12.035.
11. Visan A, Hayess K, Sittner D, Pohl EE, Riebeling C, et al. (2012) Neural differentiation of mouse embryonic stem cells as a tool to assess developmental neurotoxicity in vitro. Neurotoxicology 33: 1135-1146 doi:10.1016/j.neuro.2012. 06.006.
12. Ambros V (2000) Control of developmental timing in Caenorhabditis elegans. CurrOpinGenetDev 10: 428-433.
13. Ambros V (2001) microRNAs: tiny regulators with great potential. Cell 107: 823-826.
14. Friedman RC, Farh KK-H, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19: 92-105.
15. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
16. Li X, Jin P (2010) Roles of small regulatory RNAs in determining neuronal identity. Nature Publishing Group 11: 329-338. doi:10.1038/nrn2739.
17. O'Carroll D, Schaefer A (2013) General principals of miRNA biogenesis and regulation in the brain. Neuropsychopharmacology 38: 39-54. doi:10.1038/npp.2012.87.
18. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, et al. (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308: 833-838. (Pubitemid 40629259)
19. Huang TT, Liu YY, Huang MM, Zhao XX, Cheng LL (2010) Wnt1-cre-mediated conditional loss of Dicer results in malformation of the midbrain and cerebellum and failure of neural crest and dopaminergic differentiation in mice. Fen Zi Xi Bao Sheng Wu Xue Bao 2: 152-163. doi:10.1093/jmcb/mjq008.
20. Wu X, Song Y (2011) Preferential regulation of miRNA targets by environmental chemicals in the human genome. BMC Genomics 12: 244. doi:10.1186/1471-2164-12-244.
21. Kaur P, Armugam A, Jeyaseelan K (2012) MicroRNAs in Neurotoxicity. Journal of Toxicology 2012: 1-15. doi:10.2353/ajpath.2010.091202.
22. Smirnova L, Sittka A, Luch A (2012) On the role of low-dose effects and epigenetics in toxicology. EXS 101: 499-550. doi:10.1007/978-3-7643-8340-4-18.
23. Tal TL, Tanguay RL (2012) Non-coding RNAs - novel targets in neurotoxicity. Neurotoxicology 33: 530-544. doi:10.1016/j.neuro.2012.02.013.
24. Theunissen PT, Robinson JF, Pennings JLA, de Jong E, Claessen SMH, et al. (2012) Transcriptomic Concentration-Response Evaluation of Valproic Acid, Cyproconazole, and Hexaconazole in the Neural Embryonic Stem Cell Test (ESTn). Toxicological Sciences 125: 430-438. doi:10.1093/toxsci/kfr293.
25. Theunissen PT, Pennings JLA, Robinson JF, Claessen SMH, Kleinjans JCS, et al. (2011) Time-response evaluation by transcriptomics of methylmercury effects on neural differentiation of murine embryonic stem cells. Toxicol Sci 122: 437-447. doi:10.1093/toxsci/kfr134.
26. Pallocca G, Fabbri M, Sacco MG, Gribaldo L, Pamies D, et al. (2013) miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol 29: 239-257. doi:10.1007/s10565-013-9250-5.
27. Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 28: 1-10. doi:S0890-6238(09)00042-2 [pii];10.1016/j.reprotox.2009.02.014 [doi].
28. Bowden CL (2009) Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 11 Suppl 2: 20-33. doi:10.1111/j.1399-5618.2009.00708.x.
29. Batty N, Malouf GG, Issa JPJ (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280: 9-9. doi:10.1016/j.canlet.2009.03.013.
30. Calabresi PP, Galletti FF, Rossi CC, Sarchielli PP, Cupini LML (2007) Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 28: 8-8. doi:10.1016/j.tips.2007.02.005.
31. Boeckeler K, Adley K, Xu X, Jenkins A, Jin T, et al. (2006) The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. European Journal of Cell Biology 85: 1047-1057. doi:10.1016/j.ejcb.2006.04.013. (Pubitemid 44317602)
32. Hao Y, Creson T, Zhang L, Li P, Du F, et al. (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. JNeurosci 24: 6590-6599. doi:10.1523/JNEUROSCI.5747-03.2004. (Pubitemid 38971708)
33. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37: 103-110.
34. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741. doi:10.1074/jbc. M101287200 [doi];M101287200 [pii].
35. Briner W, Papadopoulos FC (2000) Valproate enhances N-cadherin production in Xenopus embryos. Neurotoxicol Teratol 22: 761-764. doi:10.1016/S0892- 0362(00)00086-6.
36. De Ferrari GV, Moon RT (2006) The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25: 7545-7553. doi:10.1038/sj.onc. 1210064. (Pubitemid 44885754)
37. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. NatBiotechnol 26: 1269-1275. doi:10.1038/nbt.1502.
38. Delcuve GP, Khan DH, Davie JR (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 4: 5. doi:1868-7083-4-5 [pii];10.1186/1868-7083-4-5 [doi].
39. Grandjean P, Murata K (2007) Developmental Arsenic Neurotoxicity in Retrospect. Epidemiology 18: 25-26. doi:10.1097/01.ede.0000249533.77900.74. (Pubitemid 46019617)
40. Andersen HR, Nielsen JB, Grandjean P (2000) Toxicologic evidence of developmental neurotoxicity of environmental chemicals. Toxicology 144: 121-127. doi:10.1016/S0300-483X(99)00198-5.
41. Auerbach WW, Dunmore JHJ, Fairchild-Huntress VV, Fang QQ, Auerbach ABA, et al. (2000) Establishment and chimera analysis of 129/SvEv- and C57BL/6-derived mouse embryonic stem cell lines. Biotechniques 29: 1024-1032.
42. Kaul D, Habbel P, Derkow K, Krüger C, Franzoni E, et al. (2012) Expression of Toll-like receptors in the developing brain. PLoS ONE 7: e37767-e37767. doi:10.1371/journal.pone.0037767.
43. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, et al. (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 100: 8514-8519. doi:10.1073/pnas.1432609100. (Pubitemid 36842576)
44. Seiler AE, Spielmann H (2011) The validated embryonic stem cell test to predict embryotoxicity in vitro. NatProtoc 6: 961-978. doi:nprot.2011.348 [pii];10.1038/nprot.2011.348 [doi].
45. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 157(1): 289-300
46. Schmittgen TDT, Livak KJK (2008) Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3: 1101-1108. doi:10.1038/nprot.2008. 73.
47. Smirnova L, Gräfe A, Seiler A, Schumacher S, Nitsch R, et al. (2005) Regulation of miRNA expression during neural cell specification. Eur J Neurosci 21: 1469-1477. doi:10.1111/j.1460-9568.2005.03978.x. (Pubitemid 40646593)
48. Noorbakhsh F, Ellestad KK, Maingat F, Warren KG, Han MH, et al. (2011) Impaired neurosteroid synthesis in multiple sclerosis. Brain 134: 2703-2721. doi:awr200 [pii];10.1093/brain/awr200 [doi].
49. Larsen KBK, Lutterodt MCM, Møllgård KK, Møller MM (2010) Expression of the homeobox genes OTX2 and OTX1 in the early developing human brain. J Histochem Cytochem 58: 669-678. doi:10.1369/jhc.2010.955757.
50. Grinberg I, Millen KJ (2005) The ZIC gene family in development and disease - Grinberg - 2005 - Clinical Genetics - Wiley Online Library. Clinical genetics.
51. Kultima K, Nystrom AM, Scholz B, Gustafson AL, Dencker L, et al. (2004) Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 112: 1225-1235. (Pubitemid 39199563)
52. Jergil M, Kultima K, Gustafson AL, Dencker L, Stigson M (2009) Valproic Acid-Induced Deregulation In Vitro of Genes Associated In Vivo with Neural Tube Defects. Toxicol Sci 108: 132-148. doi:10.1093/toxsci/kfp002.
53. Wulczyn FG, Smirnova L, Rybak A, Brandt C, Kwidzinski E, et al. (2007) Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J 21: 415-426. doi:10.1096/fj.06-6130com. (Pubitemid 46213489)
54. Yablonka-Reuveni Z, Day K, Vine A, Shefer G (2007) Defining the transcriptional signature of skeletal muscle stem cells. Journal of Animal Science 86: E207-E216. doi:10.2527/jas.2007-0473.
55. Ge Y, Chen J (2011) MicroRNAs in skeletal myogenesis. Cell Cycle 10: 441-448. doi:14710 [pii].
56. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, et al. (2005) Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 19: 1166-1168. doi:10.1096/fj.04-3425fje. (Pubitemid 40946453)
57. Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862-864. (Pubitemid 33032105)
58. Lee C-T, Risom T, Strauss WM (2007) Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny. DNA and Cell Biology 26: 209-218. doi:10.1089/dna.2006.0545. (Pubitemid 46776605)
59. Nimmo RA, Slack FJ (2009) An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma 118: 405-418. doi:10.1007/s00412- 009-0210-z.
60. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, et al. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89. doi:10.1038/35040556.
61. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell 129: 1401-1414. doi:10.1016/j.cell.2007.04.040. (Pubitemid 46970709)
62. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, et al. (2004) Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 5: R13.
63. McCarthy JJ (2008) MicroRNA-206: the skeletal muscle-specific myomiR. BiochimBiophysActa 1779: 682-691. doi:10.1016/j.bbagrm.2008.03.001.
64. Shi Y, Zhao X, Hsieh J, Wichterle H, Impey S, et al. (2010) MicroRNA Regulation of Neural Stem Cells and Neurogenesis. Journal of Neuroscience 30: 14931-14936. doi:10.1523/JNEUROSCI.4280-10.2010.
65. Kim HK (2006) Muscle-specific microRNA miR-206 promotes muscle differentiation. The Journal of Cell Biology 174: 677-687. doi:10.1083/jcb. 200603008.
66. Winbanks CE, Wang B, Beyer C, Koh P, White L, et al. (2011) TGF- Regulates miR-206 and miR-29 to Control Myogenic Differentiation through Regulation of HDAC4. Journal of Biological Chemistry 286: 13805-13814. doi:10.1074/jbc.M110.192625.
67. Goljanek-Whysalla K, Dylan Sweetmana, Abu-Elmagda M, Chapnikc E, Dalmayb T, et al. (2011) MicroRNA regulation of the paired-box transcriptionfactor Pax3 confers robustness to developmentaltiming of myogenesis: PNAS 1-6. doi:10.1073/pnas.1105362108/-/DCSupplemental.
68. Dey BK, Gagan J, Dutta A (2011) miR-206 and -486 induce myoblast differentiation by downregulating Pax7. MolCell Biol 31: 203-214. doi:MCB.01009-10 [pii];10.1128/MCB.01009-10 [doi].
69. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, et al. (2009) MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice. Science 326: 1549-1554. doi:10.1126/science.1181046.
70. Anderson C, Catoe H, Werner R (2006) MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res 34: 5863-5871. doi:gkl743 [pii];10.1093/nar/gkl743 [doi].
71. Redline RW, Neish A, Holmes LB, Collins T (1992) Homeobox genes and congenital malformations. Lab Invest 66: 659-670.
72. Huang H, Xie C, Sun X, Ritchie RP, Zhang J, et al. (2010) miR-10a Contributes to Retinoid Acid-induced Smooth Muscle Cell Differentiation. Journal of Biological Chemistry 285: 9383-9389. doi:10.1074/jbc.M109.095612.
73. Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barettino D (2011) MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem 286: 4150-4164. doi:M110.167817 [pii];10.1074/jbc.M110. 167817 [doi].
74. Hagiwara H, Saito F, Masaki T, Ikeda M, Nakamura-Ohkuma A, et al. (2011) Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors and myogenic repressors. Biochemical and Biophysical Research Communications 414: 826-831. doi:S0006-291X(11)01833-X [pii];10.1016/j.bbrc.2011.10.036 [doi].
75. Iezzi S, Cossu G, Nervi C, Sartorelli V, Puri PL (2002) Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci USA 99: 7757-7762. doi:10.1073/pnas.112218599. (Pubitemid 34568764)
76. Sweetman D, Goljanek K, Rathjen T, Oustanina S, Braun T, et al. (2008) Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. DevBiol 321: 491-499. doi:S0012-1606(08)01009-9 [pii];10.1016/j.ydbio.2008.06.019 [doi].
77. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, et al. (2010) TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29: 3545-3553. doi:onc2010111 [pii];10.1038/onc.2010.111 [doi].
78. Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, et al. (2009) Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 37: 123-128. doi:gkn920 [pii];10.1093/nar/gkn920 [doi].
79. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437. doi:10.1172/JCI36183.
80. Castanon I, Baylies MK (2002) A Twist in fate: evolutionary comparison of Twist structure and function. Gene 287: 11-22. (Pubitemid 34460565)
81. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG (2007) Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet 39: 259-263. doi:ng1953 [pii];10.1038/ng1953 [doi].
82. Feng Y, Cao JH, Li XY, Zhao SH (2011) Inhibition of miR-214 expression represses proliferation and differentiation of C2C12 myoblasts. Cell Biochem Funct 29: 378-383. doi:10.1002/cbf.1760 [doi].
83. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V (2009) Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. MolCell 36: 61-74. doi:S1097-2765(09)00583-8 [pii];10.1016/j.molcel.2009.08.008 [doi].
84. Liu J, Luo XJ, Xiong AW, Zhang ZD, Yue S, et al. (2010) MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via downregulation of proto-oncogene N-ras. J Biol Chem 285: 26599-26607. doi:M110.115824 [pii];10.1074/jbc.M110.115824 [doi].
85. Tarantino C, Paolella G, Cozzuto L, Minopoli G, Pastore L, et al. (2010) miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J 24: 3255-3263. doi:10.1096/fj.09-152207.
86. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14. doi:10.1186/1741-7015-6-14.
87. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, et al. (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. The Journal of Cell Biology 189: 127-141. doi:10.1083/jcb.200908151.
88. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, et al. (2011) Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. MolCell 42: 500-510. doi:10.1016/j.molcel.2011.04. 018.
89. Abdelmohsen K, Hutchison ER, Lee EK, Kuwano Y, Kim MM, et al. (2010) miR-375 inhibits differentiation of neurites by lowering HuD levels. MolCell Biol 30: 4197-4210. doi:MCB.00316-10 [pii];10.1128/MCB.00316-10 [doi].
90. Balmer NV, Weng MK, Zimmer B, Ivanova VN, Chambers SM, et al. (2012) Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet 21: 4104-4114. doi:10.1093/hmg/dds239.
91. Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, et al. (2012) Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol 87: 123-143. doi:10.1007/s00204-012-0967- 3.
92. Balmer NV, leist M (2014) Epigenetics and Transcriptomics to Detect Adverse Drug Effects in Model Systems of Human Development. Basic Clin Pharmacol Toxicol. doi:10.1111/bcpt.12203.
93. Waldmann T, Rempel E, Balmer NV, König A, Kolde R, et al. (2014) Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol 27: 408-420. doi:10.1021/tx400402j.
94. Jergil M, Forsberg M, Salter H, Stockling K, Gustafson AL, et al. (2011) Short-Time Gene Expression Response to Valproic Acid and Valproic Acid Analogs in Mouse Embryonic Stem Cells. Toxicol Sci 121: 328-342. doi:10.1093/toxsci/ kfr070.
95. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research 34: D140-D144.